Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity

Journal of Dermatological Science

Volumn 86, Issue 1, 2017, Pages 71-73

  Tanaka, Ryota ^a   Okiyama, Naoko ^a   Okune, Mari ^a   Ishitsuka, Yosuke ^a   Watanabe, Rei ^a   Furuta, Junichi ^a   Ohtsuka, Mikio ^a   Otsuka, Atsushi ^a   Maruyama, Hiroshi ^a   Fujisawa, Yasuhiro ^a   Fujimoto, Manabu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; NIVOLUMAB; TUMOR NECROSIS FACTOR; IL6 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ANAMNESIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; HUMAN; IMMUNOPATHOGENESIS; LETTER; MELANOMA; PROTEIN BLOOD LEVEL; PSORIASIS; SIDE EFFECT; UPREGULATION; AGED; BLOOD; CASE REPORT; CHEMICALLY INDUCED; DRUG ERUPTION; MALE; SKIN TUMOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; DRUG ERUPTIONS; HUMANS; INTERLEUKIN-6; MALE; MELANOMA; NIVOLUMAB; PSORIASIS; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85008721427     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.12.019     Document Type: Letter

References (10)

1. [1] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
2. [2] Ohtsuka, M., Miura, T., Mori, T., Ishikawa, M., Yamamoto, T., Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 151 (2015), 797–799.
3. [3] Lynde, C.W., Poulin, Y., Vender, R., Bourcier, M., Khalil, S., Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J. Am. Acad. Dermatol. 71 (2014), 141–150.
4. [4] Takahashi, H., Tsuji, H., Hashimoto, Y., Ishida-Yamamoto, A., Iizuka, H., Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin. Exp. Dermatol. 35 (2010), 645–649.
5. [5] Dulos, J., Carven, G.J., van Boxtel, S.J., Evers, S., Driessen-Engels, L.J., Hobo, W., et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J. Immunother. 35 (2012), 169–178.
6. [6] Lin, W.W., Karin, M., A cytokine-mediated link between innate immunity inflammation, and cancer. J. Clin. Invest. 117 (2007), 1175–1183.
7. [7] Watanabe, H., Kawaguchi, M., Fujishima, S., Ogura, M., Matsukura, S., Takeuchi, H., et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J. Invest. Dermatol. 129 (2009), 650–656.
8. [8] Zimmermann, M., Aguilera, F.B., Castellucci, M., Rossato, M., Costa, S., Lunardi, C., et al. Chromatin remodelling and autocrine TNFα are required for optimal interleukin-6 expression in activated human neutrophils. Nat. Commun., 6, 2015, 6061.
9. [9] Arican, O., Aral, M., Sasmaz, S., Ciragil, P., Serum levels of TNF-alpha, IFN-gamma IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 (2005), 273–279.
10. [10] Ocvirk, J., Stabuc, B., Rudolf, Z., Galvani, V., Curin-Serbec, V., Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients. Melanoma Res. 10 (2000), 253–258.